title: Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives.
abstract: Sucralfate, a complex of aluminium hydroxide with sulfated sucrose, forms a strong gastrointestinal tract (GIT) mucosal barrier with excellent anti-ulcer property. Because sucralfate does not undergo any significant oral absorption, sucralfate resides in the GIT for a considerable length of time. The unabsorbed sucralfate may alter the pharmacokinetics of the oral drugs by impeding its absorption and reducing the oral bioavailability. Because of the increased use of sucralfate, it was important to provide a reappraisal of the published clinical drug-drug interaction studies of sucralfate with scores of drugs. This review covers several category of drugs such as non-steroidal anti-inflammatory drugs, fluoroquinolones, histamine H2-receptor blockers, macrolides, anti-fungals, anti-diabetics, salicylic acid derivatives, steroidal anti-inflammatory drugs and provides pharmacokinetic data summary along with study design, objectives and key remarks. While the loss of oral bioavailability was significant for the fluoroquinolone class, it generally varied for other classes of drugs, suggesting that impact of the co-administration of sucralfate is manageable in clinical situations. Given the technology advancement in formulation development, it may be in order feasible to develop appropriate formulation strategies to either avoid or minimize the absorption-related issues when co-administered with sucralfate. It is recommended that consideration of both in vitro and preclinical studies may be in order to gauge the level of interaction of a drug with sucralfate. Such data may aid in the development of appropriate strategies to navigate the co-administration of sucralfate with other drugs in this age of polypharmacy.
authors.affiliation: Jubilant Biosys, 2nd Stage, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India.
authors.forename: Suresh P
authors.initials: SP
authors.lastname: Sulochana
authors.affiliation: Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Muzeeb
authors.initials: M
authors.lastname: Syed
authors.affiliation: Jubilant Biosys, 2nd Stage, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India.
authors.forename: Devaraj V
authors.initials: DV
authors.lastname: Chandrasekar
authors.affiliation: Jubilant Biosys, 2nd Stage, Industrial Suburb, Yeshwanthpur, Bangalore, 560 022, India.
authors.forename: Ramesh
authors.initials: R
authors.lastname: Mullangi
authors.affiliation: Suramus Bio, Drug Development, I Phase, J.P. Nagar, Bangalore, 560 078, India. srini.suramus@yahoo.com.
authors.forename: Nuggehally R
authors.initials: NR
authors.lastname: Srinivas
mesh_terms: D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004347:Drug Interactions; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000378:metabolism*; D013392:Sucralfate / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D004364:Pharmaceutical Preparations; D013392:Sucralfate